Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib vs Osimertinib or Afatinib in First-Line Advanced NSCLC with EGFR PACC Mutations
NCT07185997Phase 3Recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Dec 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by ArriVent BioPharma. Started Dec 2025; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07185997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185997.